Tomoyuki Miyamoto1, Masayuki Miyamoto2. 1. Department of Neurology Dokkyo Medical University Saitama Medical Center Saitama Japan. 2. Center of Sleep Medicine Dokkyo Medical University Hospital Tochigi Japan.
Abstract
BACKGROUND: The conversion rate and estimated risk of neurodegenerative diseases vary with idiopathic rapid eye movement sleep behavior disorder (IRBD). METHODS: This retrospective cohort study examined 273 patients (213 men, 60 women) with polysomnographic-confirmed IRBD (192 and 81 patients in the Sleep Center [SC] cohort and Neurological Center [NC] cohort, respectively) who were followed longitudinally. The date of diagnosis was determined as the onset of an overt neurological syndrome. The conversion rate was calculated; the risk of developing an overt neurological syndrome was estimated using the Kaplan-Meier method. RESULTS: The estimated onset risk for a neurodegenerative syndrome from the time of IRBD diagnosis when the SC and NC cohorts were combined was 11.9%, 20.3%, 33.2%, and 51.4% at three, five, seven, and ten years, respectively. The phenoconversion rate (21.7% with a mean follow-up period from the time of IRBD diagnosis of 3.9 ± 3.0 years) was lower than in prior studies, but the conversion risk increased progressively as the follow-up period increased. The majority of patients developed Lewy body disease, while multiple system atrophy was rare. The risk of developing Lewy body disease differed significantly between the SC and NC cohorts (P = 0.02). CONCLUSIONS: In this first study of a large Asian IRBD population, the estimated conversion risk leading to diagnosis differed between the two cohorts, which could be attributed to different evaluation results depending on the observed population due to a referral bias and follow-up duration. Researchers should be aware of potential selection bias in their clinical studies.
BACKGROUND: The conversion rate and estimated risk of neurodegenerative diseases vary with idiopathic rapid eye movement sleep behavior disorder (IRBD). METHODS: This retrospective cohort study examined 273 patients (213 men, 60 women) with polysomnographic-confirmed IRBD (192 and 81 patients in the Sleep Center [SC] cohort and Neurological Center [NC] cohort, respectively) who were followed longitudinally. The date of diagnosis was determined as the onset of an overt neurological syndrome. The conversion rate was calculated; the risk of developing an overt neurological syndrome was estimated using the Kaplan-Meier method. RESULTS: The estimated onset risk for a neurodegenerative syndrome from the time of IRBD diagnosis when the SC and NC cohorts were combined was 11.9%, 20.3%, 33.2%, and 51.4% at three, five, seven, and ten years, respectively. The phenoconversion rate (21.7% with a mean follow-up period from the time of IRBD diagnosis of 3.9 ± 3.0 years) was lower than in prior studies, but the conversion risk increased progressively as the follow-up period increased. The majority of patients developed Lewy body disease, while multiple system atrophy was rare. The risk of developing Lewy body disease differed significantly between the SC and NC cohorts (P = 0.02). CONCLUSIONS: In this first study of a large Asian IRBD population, the estimated conversion risk leading to diagnosis differed between the two cohorts, which could be attributed to different evaluation results depending on the observed population due to a referral bias and follow-up duration. Researchers should be aware of potential selection bias in their clinical studies.
Entities:
Keywords:
Lewy body disease; Parkinson's disease; REM sleep behavior disorder; dementia with Lewy bodies; phenoconversion
Authors: Jean-François Gagnon; Mélanie Vendette; Ronald B Postuma; Catherine Desjardins; Jessica Massicotte-Marquez; Michel Panisset; Jacques Montplaisir Journal: Ann Neurol Date: 2009-07 Impact factor: 10.422
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka Journal: Neurology Date: 2017-06-07 Impact factor: 9.910
Authors: Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte Journal: Neurosci Biobehav Rev Date: 2019-05-24 Impact factor: 8.989
Authors: Parichita Choudhury; Jonathan Graff-Radford; Jeremiah A Aakre; Lincoln Wurtz; David S Knopman; Neill R Graff-Radford; Kejal Kantarci; Leah K Forsberg; Julie A Fields; Otto Pedraza; Qin Chen; Toji Miyagawa; Gregory S Day; Philip Tipton; Rodolfo Savica; Hugo Botha; Christian Lachner; Brynn Dredla; R Ross Reichard; Ronald C Petersen; Dennis W Dickson; Bradley F Boeve; Tanis J Ferman Journal: Alzheimers Dement Date: 2021-11-11 Impact factor: 16.655